Overview

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Status:
Terminated

Trial end date:
2019-07-10

Target enrollment:

Participant gender:

Summary

The purpose of this Phase 1 of the study is to evaluate the effect of food on the pharmacokinetics (PK) of oprozomib, the drug-drug interaction of oprozomib with midazolam, and the safety and tolerability of oprozomib in patients with advanced malignancies

Phase:

Phase 1

Details

Lead Sponsor:

Amgen
Onyx Therapeutics, Inc.

Treatments:

Midazolam